Hepatic artery infusion chemotherapy (HAIC) is a treatment modality for advanced hepatocellular carcinoma (HCC). 肝动脉输注化疗(HAIC)是治疗晚期肝癌(HCC)的一种治疗方式。 HAIC entails infusing chemotherapeutic agents directly into hepatic tu...
Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related death worldwide. 肝细胞癌(HCC)是全球癌症相关死亡的第三大原因。 Unlike most solid cancers, future incidence and mortality rates for HCC were projected to largely in...
经动脉化疗栓塞(TACE)是一种已建立的方法HCC的局部治疗。Transarterial chemoembolization (TACE) is an established locoregional therapy for HCC. 然而对栓塞治疗后的肿瘤反应有多种原因,而且没有真正的共识。Tumor response varies with multiple cause...
系统审查的棱流程图详细说明了数据库搜索、筛选的引用次数和检索到的全文。 初始结果 The OS was reported in all eight trials. 在所有8项试验中都报道了整体生存率(OS)。 The corresponding HR was reported in three trials, obtained through correspo...
Recently, the use of Yttrium-90 transarterial radioembolization in non-surgical hepatocellular carcinoma was suggested but the evidence supporting its use is unclear. 最近,有人建议使用钇-90经动脉放射栓塞治疗非手术性肝细胞癌,但支持其使用...
经动脉疗法 中期肿瘤(BCLC B期)患者应考虑经动脉疗法。主要的治疗方法是经动脉化疗栓塞(TACE),即动脉内输注一种细胞毒性药物,然后立即栓塞肿瘤的供血血管。邻近的非肿瘤肝组织通常不受TACE的影响,因为与肿瘤不同,前者的血液供应主要来自门静脉。失代...
消融治疗 建议BCLC 0期或不适合手术治疗的肿瘤患者行肿瘤消融治疗。主要方法是影像引导下经皮射频消融术,通过升高肿瘤内温度导致肿瘤坏死。与切除相比,消融治疗并发症较少,但对较大肿瘤的局部控制较差。 对于一些直径小于2cm且在肝实质内位置良好的孤立性...